Jefferies Group’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $1.59M | Buy |
29,954
+22,454
| +299% | +$1.25M | 0.01% | 678 |
|
|
2022
Q2 | $437K | Buy |
+7,500
| New | +$491K | ﹤0.01% | 1052 |
|
|
2021
Q4 | – | Sell |
-28,755
| Closed | -$1.61M | – | 1907 |
|
|
2021
Q3 | $1.61M | Buy |
+28,755
| New | +$1.66M | 0.01% | 829 |
|
|
2021
Q2 | – | Sell |
-11,000
| Closed | -$771K | – | 1920 |
|
|
2021
Q1 | $771K | Sell |
11,000
-8,586
| -44% | -$613K | 0.01% | 983 |
|
|
2020
Q4 | $1.17M | Buy |
19,586
+6,550
| +50% | +$384K | 0.01% | 888 |
|
|
2020
Q3 | $784K | Buy |
13,036
+6,036
| +86% | +$351K | 0.01% | 866 |
|
|
2020
Q2 | $367 | Sell |
7,000
-188,393
| -96% | -$7.87M | ﹤0.01% | 978 |
|
|
2020
Q1 | $6.55M | Buy |
+195,393
| New | +$8.12M | 0.07% | 235 |
|
|
2019
Q4 | – | Sell |
-35
| Closed | -$1K | – | 2879 |
|
|
2019
Q3 | $1K | Sell |
35
-37,500
| -100% | -$1.5M | ﹤0.01% | 2654 |
|
|
2019
Q2 | $1.63M | Buy |
37,535
+14,054
| +60% | +$597K | 0.01% | 1031 |
|
|
2019
Q1 | $894K | Buy |
23,481
+8,044
| +52% | +$314K | 0.01% | 1322 |
|
|
2018
Q4 | $664K | Sell |
15,437
-5,919
| -28% | -$276K | 0.01% | 1360 |
|
|
2018
Q3 | $1.05M | Buy |
21,356
+17,960
| +529% | +$776K | 0.01% | 1304 |
|
|
2018
Q2 | $109K | Buy |
+3,396
| New | +$117K | ﹤0.01% | 2122 |
|
|
2018
Q1 | – | Sell |
-10,303
| Closed | -$470K | – | 2583 |
|
|
2017
Q4 | $470K | Sell |
10,303
-2,939
| -22% | -$116K | ﹤0.01% | 1759 |
|
|
2017
Q3 | $497K | Sell |
13,242
-11,052
| -45% | -$445K | ﹤0.01% | 1637 |
|
|
2017
Q2 | $1.16M | Sell |
24,294
-7,787
| -24% | -$361K | 0.01% | 1215 |
|
|
2017
Q1 | $1.46M | Buy |
+32,081
| New | +$1.39M | 0.01% | 1074 |
|
|
2016
Q4 | – | Sell |
-10,721
| Closed | -$367K | – | 2406 |
|
|
2016
Q3 | $367K | Buy |
10,721
+714
| +7% | +$28K | ﹤0.01% | 1737 |
|
|
2016
Q2 | $338K | Buy |
+10,007
| New | +$492K | ﹤0.01% | 1614 |
|
|
2016
Q1 | – | Sell |
-5,000
| Closed | -$292K | – | 2485 |
|
|
2015
Q4 | $384K | Buy |
5,000
+1,800
| +56% | +$102K | ﹤0.01% | 1669 |
|
|
2015
Q3 | $132K | Buy |
3,200
+2,600
| +433% | +$159K | ﹤0.01% | 2013 |
|
|
2015
Q2 | $42K | Buy |
+600
| New | +$47.3K | ﹤0.01% | 2485 |
|
|
2014
Q3 | – | Sell |
-10,500
| Closed | -$965K | – | 2361 |
|
|
2014
Q2 | $965K | Sell |
10,500
-66,783
| -86% | -$5.09M | 0.01% | 919 |
|
|
2014
Q1 | $5.41M | Buy |
+77,283
| New | +$5.26M | 0.05% | 291 |
|
|
2013
Q4 | – | Sell |
-7,708
| Closed | -$371K | – | 2153 |
|
|
2013
Q3 | $371K | Sell |
7,708
-16,827
| -69% | -$613K | ﹤0.01% | 1336 |
|
|
2013
Q2 | $712K | Buy |
+24,535
| New | +$710K | 0.01% | 919 |
|
Other funds holding PCRX
AC
SCM
SIMG
Jefferies Group's PCRX Position: Q3 2022 in Review
Jefferies Group increased its Pacira BioSciences (PCRX) stake by 299% in Q3 2022, buying an estimated $1.25M and bringing the position to 29,954 shares worth $1.59M. The position accounts for 0.01% of the portfolio, ranked #678.
Jefferies Group first reported a position in PCRX in Q2 2013 and has held it in 27 quarters since. The position peaked at $6.55M in Q1 2020. 273 funds tracked by Wall St. Rank hold PCRX as of Q3 2022.
- Jefferies Group held 29,954 shares of Pacira BioSciences worth $1.59M as of Q3 2022.
- Jefferies Group bought 22,454 Pacira BioSciences shares in Q3 2022, an estimated $1.25M.
- Pacira BioSciences made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #678 holding.
- Jefferies Group first reported a position in Pacira BioSciences in Q2 2013 and has held it in 27 quarters since.
- Jefferies Group's Pacira BioSciences position peaked at $6.55M in Q1 2020.
- 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.